These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32557296)

  • 21. In Silico Methods for Development of Generic Drug-Device Combination Orally Inhaled Drug Products.
    Walenga RL; Babiskin AH; Zhao L
    CPT Pharmacometrics Syst Pharmacol; 2019 Jun; 8(6):359-370. PubMed ID: 31044532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishing bioequivalence for inhaled drugs; weighing the evidence.
    Daley-Yates PT; Parkins DA
    Expert Opin Drug Deliv; 2011 Oct; 8(10):1297-308. PubMed ID: 21699442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
    Lau M; Young PM; Traini D
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First approval of generic dry powder inhaler drug products in Japan.
    Kuribayashi R; Myoenzono A
    Drug Deliv Transl Res; 2020 Oct; 10(5):1517-1519. PubMed ID: 32613551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
    Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
    Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patent Challenges And Litigation On Inhalers For Asthma And COPD.
    Reddy S; Beall RF; Tu SS; Kesselheim AS; Feldman WB
    Health Aff (Millwood); 2023 Mar; 42(3):398-406. PubMed ID: 36877911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhalatory therapy training: a priority challenge for the physician.
    Melani AS
    Acta Biomed; 2007 Dec; 78(3):233-45. PubMed ID: 18330086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Considerations for Designing In Vitro Bioequivalence (IVBE) Studies for Pressurized Metered Dose Inhalers (pMDIs) with Spacer or Valved Holding Chamber (S/VHC) Add-on Devices.
    Sandell D; Mitchell JP
    J Aerosol Med Pulm Drug Deliv; 2015 Jun; 28(3):156-81. PubMed ID: 25089555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guidance on handheld inhalers in asthma and COPD guidelines.
    Dekhuijzen PN; Bjermer L; Lavorini F; Ninane V; Molimard M; Haughney J
    Respir Med; 2014 May; 108(5):694-700. PubMed ID: 24636812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing drug delivery in COPD: The role of inhaler devices.
    Rogliani P; Calzetta L; Coppola A; Cavalli F; Ora J; Puxeddu E; Matera MG; Cazzola M
    Respir Med; 2017 Mar; 124():6-14. PubMed ID: 28284323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a dry powder inhaler, the Ultrahaler, containing triamcinolone acetonide using in vitro-in vivo relationships.
    Lim JG; Shah B; Rohatagi S; Bell A
    Am J Ther; 2006; 13(1):32-42. PubMed ID: 16428920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple inhalers confuse asthma patients.
    van der Palen J; Klein JJ; van Herwaarden CL; Zielhuis GA; Seydel ER
    Eur Respir J; 1999 Nov; 14(5):1034-7. PubMed ID: 10596686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the use of dry powder inhalers in situations perceived as constrained.
    Borgström L
    J Aerosol Med; 2001; 14(3):281-7. PubMed ID: 11693839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhalation devices: from basic science to practical use, innovative vs generic products.
    Pirozynski M; Sosnowski TR
    Expert Opin Drug Deliv; 2016 Nov; 13(11):1559-1571. PubMed ID: 27267298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of nebulized therapy in the management of COPD: evidence and recommendations.
    Dhand R; Dolovich M; Chipps B; Myers TR; Restrepo R; Farrar JR
    COPD; 2012 Feb; 9(1):58-72. PubMed ID: 22292598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guidelines for devices and choices.
    Everard ML
    J Aerosol Med; 2001; 14 Suppl 1():S59-64. PubMed ID: 11424895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scientific and regulatory activities initiated by the U.S. food and drug administration to foster approvals of generic dry powder inhalers: Quality perspective.
    El-Gendy N; Bertha CM; Abd El-Shafy M; Gaglani DK; Babiskin A; Bielski E; Boc S; Dhapare S; Fang L; Feibus K; Kaviratna A; Li BV; Luke MC; Ma T; Newman B; Spagnola M; Walenga RL; Zhao L
    Adv Drug Deliv Rev; 2022 Oct; 189():114519. PubMed ID: 36038083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
    Albertson TE; Chenoweth JA; Pearson SJ; Murin S
    Expert Opin Pharmacother; 2020 Feb; 21(2):213-231. PubMed ID: 31955671
    [No Abstract]   [Full Text] [Related]  

  • 39. Integration of dose counters in pressurized metered-dose inhalers for patients with asthma and chronic obstructive pulmonary disease: review of evidence.
    Kaur I; Aggarwal B; Gogtay J
    Expert Opin Drug Deliv; 2015 Aug; 12(8):1301-10. PubMed ID: 25564302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aerosol devices and asthma therapy.
    Berger W
    Curr Drug Deliv; 2009 Jan; 6(1):38-49. PubMed ID: 19418954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.